S
Saar Gill
Researcher at University of Pennsylvania
Publications - 210
Citations - 10126
Saar Gill is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Chimeric antigen receptor & Immunotherapy. The author has an hindex of 38, co-authored 168 publications receiving 6813 citations. Previous affiliations of Saar Gill include Mayo Clinic & Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo,David M. Barrett,Kathryn L. Black,Asen Bagashev,Derek A. Oldridge,Glendon S. Wu,Robyn T. Sussman,Claudia Lanauze,Marco Ruella,Matthew R. Gazzara,Nicole M. Martinez,Colleen T. Harrington,Elaine Y. Chung,Jessica Perazzelli,Ted J. Hofmann,Shannon L. Maude,Pichai Raman,Alejandro Barrera,Saar Gill,Simon F. Lacey,J. Joseph Melenhorst,David Allman,Elad Jacoby,Terry J. Fry,Crystal L. Mackall,Yoseph Barash,Kristen W. Lynch,John M. Maris,Stephan A. Grupp,Andrei Thomas-Tikhonenko +29 more
TL;DR: It is discovered that the underlying mechanism is the selection for preexisting alternatively spliced CD19 isoforms with the compromised CART-19 epitope, which suggests a possibility of targeting alternative CD19 ectodomains, which could improve survival of patients with B-cell neoplasms.
Journal ArticleDOI
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao,Ash A. Alizadeh,Chad Tang,June Helen Myklebust,June Helen Myklebust,Bindu Varghese,Saar Gill,Max Jan,Adriel C. Cha,Charles Chan,Brent T. Tan,Christopher Y. Park,Feifei Zhao,Holbrook E Kohrt,Raquel Malumbres,Javier Briones,Randy D. Gascoyne,Izidore S. Lossos,Ronald Levy,Irving L. Weissman,Ravindra Majeti +20 more
TL;DR: The eradication of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking anti-CD47 antibody, which synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers.
Journal ArticleDOI
Human chimeric antigen receptor macrophages for cancer immunotherapy.
Michael Klichinsky,Marco Ruella,Olga Shestova,Xueqing Maggie Lu,Andrew Best,Martha Zeeman,Maggie Schmierer,Konrad Gabrusiewicz,Nicholas R. Anderson,Nicholas E. Petty,Katherine D. Cummins,Feng Shen,Xinhe Shan,Kimberly Veliz,Kristin Blouch,Yumi Yashiro-Ohtani,Saad S. Kenderian,Saad S. Kenderian,Miriam Y. Kim,Miriam Y. Kim,Roddy S. O’Connor,Stephen R. Wallace,Miroslaw Kozlowski,Dylan M. Marchione,Maksim Shestov,Benjamin A. Garcia,Carl H. June,Saar Gill +27 more
TL;DR: It is found that a chimeric adenoviral vector overcame the inherent resistance of primary human macrophages to genetic manipulation and imparted a sustained pro-inflammatory (M1) phenotype in humanized mice.
Journal ArticleDOI
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella,David M. Barrett,Saad S. Kenderian,Olga Shestova,Ted J. Hofmann,Jessica Perazzelli,Michael Klichinsky,Vania Aikawa,Farzana Nazimuddin,Miroslaw Kozlowski,John Scholler,Simon F. Lacey,J. Joseph Melenhorst,Jennifer J.D. Morrissette,David A. Christian,Christopher A. Hunter,Michael Kalos,Michael Kalos,David L. Porter,Carl H. June,Stephan A. Grupp,Saar Gill +21 more
TL;DR: It is found that in primary patient samples, the IL-3 receptor α chain CD123 was highly expressed on leukemia-initiating cells and CD19-negative blasts in bulk B-ALL at baseline and at relapse after CART19 administration, indicating that targeting CD19 and CD123 on leukemic blasts represents an effective strategy for treating and preventing antigen-loss relapses occurring after CD19
Journal ArticleDOI
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
Saar Gill,Sarah K. Tasian,Marco Ruella,Olga Shestova,Yong Li,David L. Porter,Martin Carroll,Gwenn Danet-Desnoyers,John Scholler,Stephan A. Grupp,Carl H. June,Michael Kalos +11 more
TL;DR: It is shown that CD123 is a good target for AML-directed CAR therapy, because its expression increases over time in vivo even in initially CD123(dim) populations, and that human CD123-redirected T cells (CART123) eradicate primary AML in immunodeficient mice.